IGC IGC Pharma, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1326205 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.9%
TTM net income YoY-25.8%
TTM EPS YoY7.4%
Revenue 3-yr CAGR-2.1%
Net income 3-yr CAGR—
Margins
Gross margin16.5%
Operating margin-802.7%
Net margin-643.7%
FCF margin-415.2%
EBITDA margin-786.5%
Returns
ROE-111.1%
ROA-83.3%
ROIC (approx.)-120.6%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets33.2%
Debt / equity0.00x
Current ratio0.42x
Interest coverage-1,685.67x
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q42025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $328,000 | $265,000 | $317,000 | $350,000 | $191,000 | $328,000 | $330,000 | $257,000 |
| Cost of revenue | $267,000 | $217,000 | $262,000 | $306,000 | $92,000 | $174,000 | $176,000 | $153,000 |
| Gross profit | $61,000 | $48,000 | $55,000 | $44,000 | $99,000 | $154,000 | $154,000 | $104,000 |
| R&D expense | $1.01M | $1.39M | $1.27M | $1.48M | $1.59M | $851,000 | $997,000 | $852,000 |
| SG&A expense | $979,000 | $1.44M | $1.24M | $1.50M | $1.41M | $1.21M | $570,000 | $1.13M |
| Operating income | -$1.93M | -$2.78M | -$2.46M | -$2.94M | -$2.90M | -$1.91M | -$1.41M | -$1.88M |
| Interest expense | $1,000 | $2,000 | $1,000 | $2,000 | $1,000 | $1,000 | $2,000 | $2,000 |
| Pretax income | -$2.05M | -$2.94M | -$2.40M | -$726,000 | -$1.82M | -$1.60M | -$1.20M | -$1.83M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.05M | -$2.94M | -$2.40M | -$726,000 | -$1.82M | -$1.60M | -$1.20M | -$1.83M |
| EBITDA | -$1.89M | -$2.74M | -$2.40M | -$2.88M | -$2.79M | -$1.78M | -$1.26M | -$1.73M |
| EPS (basic) | -0.02 | -0.03 | -0.02 | — | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS (diluted) | -0.02 | -0.03 | -0.02 | — | -0.02 | -0.02 | -0.02 | -0.02 |
| Weighted avg. shares (diluted) | 109.49M | 100.33M | 98.16M | — | 90.46M | 83.03M | 79.66M | 77.63M |
| Balance sheet | ||||||||
| Cash & equivalents | $377,000 | $331,000 | $207,000 | $900,000 | $1.10M | $454,000 | $405,000 | $470,000 |
| Short-term investments | $36,000 | $23,000 | $28,000 | $38,000 | $25,000 | — | $0 | — |
| Receivables | $68,000 | $56,000 | $37,000 | $12,000 | $41,000 | $87,000 | $34,000 | $49,000 |
| Inventory | $643,000 | $640,000 | $638,000 | $640,000 | $658,000 | $1.35M | $1.36M | $1.43M |
| Current assets | $1.31M | $1.26M | $1.15M | $1.79M | $2.00M | $2.15M | $2.90M | $3.05M |
| PP&E, net | $2.03M | $2.07M | $2.10M | $2.14M | $2.17M | $3.10M | $3.22M | $3.35M |
| Intangibles | $5.74M | $5.51M | $5.27M | $5.10M | $4.88M | $2.00M | $1.85M | $1.87M |
| Total assets | $9.73M | $9.50M | $9.19M | $9.71M | $9.74M | $7.94M | $8.75M | $9.08M |
| Current liabilities | $3.10M | $3.21M | $2.87M | $2.16M | $1.51M | $1.73M | $2.26M | $2.66M |
| Short-term debt | — | — | — | $3,000 | $4,000 | $3,000 | $3,000 | $3,000 |
| Long-term debt | — | — | — | $131,000 | $132,000 | $133,000 | $134,000 | $134,000 |
| Total debt | — | — | — | $134,000 | $136,000 | $136,000 | $137,000 | $137,000 |
| Total liabilities | $3.23M | $3.36M | $3.06M | $2.29M | $1.65M | $1.86M | $2.42M | $2.82M |
| Shareholders' equity | $6.50M | $6.13M | $6.12M | $7.42M | $8.09M | $6.08M | $6.33M | $6.26M |
| Net debt | — | — | — | -$766,000 | -$969,000 | -$318,000 | -$268,000 | -$333,000 |
| Shares outstanding | 114.35M | 102.42M | 98.80M | 95.04M | 91.96M | 84.14M | 80.88M | 78.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.42M | -$1.35M | -$1.22M | -$1.22M | -$2.09M | -$1.41M | -$730,000 | -$1.32M |
| Capital expenditure | $0 | $5,000 | $1,000 | $12,000 | $29,000 | $8,000 | $18,000 | $27,000 |
| Free cash flow | -$1.42M | -$1.35M | -$1.22M | -$1.24M | -$2.12M | -$1.42M | -$748,000 | -$1.34M |
| Investing cash flow | -$193,000 | -$254,000 | -$170,000 | -$228,000 | -$374,000 | $580,000 | -$142,000 | -$104,000 |
| Financing cash flow | $1.67M | $1.73M | $710,000 | $1.26M | $3.11M | $851,000 | $805,000 | $345,000 |
| Depreciation & amortization | $41,000 | $41,000 | $58,000 | $64,000 | $106,000 | $127,000 | $154,000 | $144,000 |
| Stock-based compensation | -$200,000 | $200,000 | $4.00M | -$100,000 | $730,000 | $4.70M | $455,000 | $381,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.